Skip to main content
SpringerLink
Log in

Oral Non-biologic Therapies and Non-pharmacological Therapies in PsA

  • Chapter
  • First Online:
Psoriatic Arthritis and Psoriasis

  • 1753 Accesses

Abstract

Traditional disease-modifying antirheumatic drugs (DMARD) are the first line for the treatment of psoriatic arthritis (PsA) globally, in spite of the lack of evidence from randomized control trials. Most of the evidence comes from observational studies that will be reviewed in this chapter. Rehabilitation in rheumatology focuses on prevention of functional disorders of the musculoskeletal system, maintenance of working ability and prevention of care dependency. Rehabilitation and physical therapy is part of non-pharmacological treatment in patients with rheumatic disease. Few studies have been identified in PsA, related to this issue, and are included in this review. Finally, surgery is preferably preventable, but necessary in some cases. Evidence suggests that results of orthopedic surgery in PsA are similar to those reported in other inflammatory diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Soriano ER. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis. J Rheumatol Suppl. 2012;89:67–70. doi:10.3899/jrheum.120248.

    Article  PubMed  Google Scholar 

  2. Helliwell PS, Taylor WJ, Group CS. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs – comparison of drugs and adverse reactions. J Rheumatol. 2008;35(3):472–6.

    PubMed  Google Scholar 

  3. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33(7):1422–30.

    PubMed  Google Scholar 

  4. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis. 2008;67(6):855–9. doi:10.1136/ard.2007.072652.

    Article  PubMed  CAS  Google Scholar 

  5. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, van der Heijde D, Emery P, Smolen JS, Marzo-Ortega H. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–26. doi:10.1136/ard.2011.150995.

    Article  PubMed  CAS  Google Scholar 

  6. Acosta Felquer ML, Coates LC, Soriano ER, Ranza R, Espinoza LR, Helliwell PS, FitzGerald O, McHugh N, Roussou E, Mease PJ. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol. 2014;41(11):2277–85. doi:10.3899/jrheum.140876.

    Article  PubMed  Google Scholar 

  7. Soriano ER. Treatment guidelines for psoriatic arthritis. Int J Clin Rheumatol. 2009;4:329–42.

    Article  CAS  Google Scholar 

  8. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P, European League Against R. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12. doi:10.1136/annrheumdis-2011-200350.

    Google Scholar 

  9. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, Cathcart ES, Samuelson Jr CO, Solsky MA, Kaplan SB, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27(4):376–81.

    Article  PubMed  CAS  Google Scholar 

  10. Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, Di Minno MN, Costa L, Del Puente A. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27(7):823–6. doi:10.1007/s10067-007-0787-7.

    Article  PubMed  Google Scholar 

  11. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O’Keeffe AG, Maddison PJ, Scott DL. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. 2012;51(8):1368–77. doi:10.1093/rheumatology/kes001.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P, Treatment of Psoriatic Arthritis Study G. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50(6):1939–50. doi:10.1002/art.20253.

    Article  PubMed  CAS  Google Scholar 

  13. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher Jr HR, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2013–20.

    Article  PubMed  CAS  Google Scholar 

  14. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008;35(3):469–71.

    PubMed  CAS  Google Scholar 

  15. Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl. 2009;83:78–80. doi:10.3899/jrheum.090234.

    Article  PubMed  Google Scholar 

  16. Baranauskaite A, Raffayova H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N, investigators R. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71(4):541–8. doi:10.1136/ard.2011.152223.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–6. doi:10.1136/annrheumdis-2013-205056.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Cutolo M, Myerson G, Fleischmann R, Liote F, Diaz-Gonzalez F, Van den Bosch F, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). Arthritis Rheum. 2013;65(Suppl):S346.

    Google Scholar 

  19. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64(10):3156–67. doi:10.1002/art.34627.

    Article  PubMed  CAS  Google Scholar 

  20. Wells A, Edwards C, Aea A. Apremilast in the treatment of DMARD-naive psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4). Arthritis Rheum. 2013;65(12):3320–1.

    Google Scholar 

  21. A Phase 3, Multi Site, Randomized, Double Blind Study of the Long-Term Safety, Tolerability and Efficacy of 2 Oral Doses of CP 690,550 in Subjects with Moderate to Severe Plaque Psoriasis and/or Psoriatic Arthritis. https://clinicaltrials.gov/ct2/show/NCT01519089?term=A3921137&rank=1. Last accessed on 10 July 2015.

  22. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S132–7.

    PubMed  CAS  Google Scholar 

  23. Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology. 2008;47(6):872–6. doi:10.1093/rheumatology/ken059.

    Article  PubMed  CAS  Google Scholar 

  24. Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rodevand E, Kaufmann C, Mikkelsen K, Kvien TK. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(4):671–6. doi:10.1136/ard.2009.113308.

    Article  PubMed  CAS  Google Scholar 

  25. Mori Y, Kuwahara Y, Chiba S, Itoi E. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis. Mod Rheumatol. 2014;25(3):431–4. doi: 10.3109/14397595.2014.958891.

    Google Scholar 

  26. Taylor WJ, Korendowych E, Nash P, Helliwell PS, Choy E, Krueger GG, Soriano ER, McHugh NJ, Rosen CF. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol. 2008;35(7):1454–7.

    PubMed  CAS  Google Scholar 

  27. Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90(6):711–6.

    Article  PubMed  Google Scholar 

  28. Behrens F, Finkenwirth C, Pavelka K, Stolfa J, Sipek-Dolnicar A, Thaci D, Burkhardt H. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res. 2013;65(3):464–70. doi:10.1002/acr.21848.

    Article  CAS  Google Scholar 

  29. Asiri A, Thavaneswaran A, Kalman-Lamb G, Chandran V, Gladman DD. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol. 2014;32(5):728–31.

    PubMed  Google Scholar 

  30. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998;25(10):1957–61.

    PubMed  CAS  Google Scholar 

  31. Paccou J, Wendling D. Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis. Joint Bone Spine. 2014. doi:10.1016/j.jbspin.2014.05.003.

    Google Scholar 

  32. Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008;67(3):364–9. doi:10.1136/ard.2007.073544.

    Article  PubMed  CAS  Google Scholar 

  33. Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Rifbjerg-Madsen S, Lorenzen T, Hetland ML. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382–90. doi:10.1002/art.30117.

    Article  PubMed  Google Scholar 

  34. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rodevand E, Kalstad S, Mikkelsen K, Kvien TK. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2012-202347.

    Google Scholar 

  35. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90. doi:10.1016/j.bcp.2012.01.001.

    Article  PubMed  CAS  Google Scholar 

  36. Schett G, Mease P, Gladman D. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in physical function in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):143.

    Google Scholar 

  37. Cutolo M, Mease P, Gladman D. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):135–6.

    Google Scholar 

  38. Edwards C, Blanco F, Crowley J, C-C H, Stevens R, Birbara CL-t-wroap, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [abstract]. Arthritis Rheum. 2013;65(Suppl):S132. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [abstract]. Arthritis Rheum. 2013;65(Suppl):S132.

    Google Scholar 

  39. Mease PJ, Kavanaugh A, Adebajo AO, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three phase 3, randomized, controlled trials. Arthritis Rheum. 2013;65:S151.

    Google Scholar 

  40. Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16(9):443. doi:10.1007/s11926-014-0443-6.

    Article  PubMed  Google Scholar 

  41. Meier FM, McInnes IB. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol. 2014;28(4):605–24. doi:10.1016/j.berh.2014.10.017.

    Article  PubMed  Google Scholar 

  42. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77. doi:10.1111/j.1365-2133.2012.11168.x.

    Article  PubMed  CAS  Google Scholar 

  43. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2013;28(2):192–203. doi:10.1111/jdv.12081.

    Article  PubMed  Google Scholar 

  44. Luttosch F, Baerwald C. Rehabilitation in rheumatology. Internist (Berl). 2010;51(10):1239–45. doi:10.1007/s00108-010-2626-1.

    Article  CAS  Google Scholar 

  45. Lubrano E, Spadaro A, Parsons WJ, Atteno M, Ferrara N. Rehabilitation in psoriatic arthritis. J Rheumatol Suppl. 2009;83:81–2. doi:10.3899/jrheum.09235.

    Article  PubMed  Google Scholar 

  46. Walker UA, Uhl M, Weiner SM, Warnatz K, Lange-Nolde A, Dertinger H, Peter HH, Jurenz SA. Analgesic and disease modifying effects of interferential current in psoriatic arthritis. Rheumatol Int. 2006;26(10):904–7. doi:10.1007/s00296-006-0102-y.

    Article  PubMed  CAS  Google Scholar 

  47. Hashkes PJ. Beneficial effect of climatic therapy on inflammatory arthritis at Tiberias Hot Springs. Scand J Rheumatol. 2002;31(3):172–7.

    Article  PubMed  Google Scholar 

  48. Sukenik S, Baradin R, Codish S, Neumann L, Flusser D, Abu-Shakra M, Buskila D. Balneotherapy at the Dead Sea area for patients with psoriatic arthritis and concomitant fibromyalgia. Isr Med Assoc J. 2001;3(2):147–50.

    PubMed  CAS  Google Scholar 

  49. Lubrano E, Helliwell P, Parsons W, Emery P, Veale D. Patient education in psoriatic arthritis: a cross sectional study on knowledge by a validated self-administered questionnaire. J Rheumatol. 1998;25(8):1560–5.

    PubMed  CAS  Google Scholar 

  50. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33(7):1431–4.

    PubMed  Google Scholar 

  51. Dougados M, Revel M, Khan MA. Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol. 1998;12(4):717–36.

    Article  PubMed  CAS  Google Scholar 

  52. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34(5):1167–70.

    PubMed  Google Scholar 

  53. Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27(5):1247–50.

    PubMed  CAS  Google Scholar 

  54. Zangger P, Gladman DD, Bogoch ER. Musculoskeletal surgery in psoriatic arthritis. J Rheumatol. 1998;25(4):725–9.

    PubMed  CAS  Google Scholar 

  55. Day MS, Nam D, Goodman S, Su EP, Figgie M. Psoriatic arthritis. J Am Acad Orthop Surg. 2012;20(1):28–37. doi:10.5435/JAAOS-20-01-028.

    Article  PubMed  Google Scholar 

  56. Zangger P, Esufali ZH, Gladman DD, Bogoch ER. Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis. J Rheumatol. 2000;27(4):967–74.

    PubMed  CAS  Google Scholar 

  57. Michet CJ, Mason TG, Mazlumzadeh M. Hip joint disease in psoriatic arthritis: risk factors and natural history. Ann Rheum Dis. 2005;64(7):1068–70. doi:10.1136/ard.2004.022228.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  58. Fiocco U, Cozzi L, Rigon C, Chieco-Bianchi F, Baldovin M, Cassisi GA, Gallo C, Doria A, Favaro MA, Piccoli A, de Candia A, Rubaltelli L, Todesco S. Arthroscopic synovectomy in rheumatoid and psoriatic knee joint synovitis: long-term outcome. Br J Rheumatol. 1996;35(5):463–70.

    Article  PubMed  CAS  Google Scholar 

  59. Belsky MR, Feldon P, Millender LH, Nalebuff EA, Phillips C. Hand involvement in psoriatic arthritis. J Hand Surg Am. 1982;7(2):203–7.

    Article  PubMed  CAS  Google Scholar 

  60. Rose JH, Belsky MR. Psoriatic arthritis in the hand. Hand Clin. 1989;5(2):137–44.

    PubMed  CAS  Google Scholar 

  61. Buryanov A, Kotiuk V, Kvasha V, Samokhin A. Three- to six-year results of metacarpophalangeal joints arthroplasty in psoriatic arthritis. J Long Term Eff Med Implants. 2013;23(4):285–92.

    Article  PubMed  Google Scholar 

  62. Lofin I, Levine B, Badlani N, Klein GR, Jaffe WL. Psoriatic arthritis and arthroplasty: a review of the literature. Bull NYU Hosp Jt Dis. 2008;66(1):41–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Instituto Universitario Hospital Italiano de Buenos Aires, Peron 4190 (1181), CABA, Buenos Aires, Argentina

    Enrique Roberto Soriano MD, MSC

  2. Rheumatology Unit, Internal Medical Service, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina

    María Laura Acosta Felquer MD

Authors
  1. Enrique Roberto Soriano MD, MSC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Laura Acosta Felquer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Enrique Roberto Soriano MD, MSC .

Editor information

Editors and Affiliations

  1. Faculty of Medicine, University of Sheffield, Sheffield, United Kingdom

    Adewale Adebajo

  2. Faculty of Medicine, University of Geneva, Geneva 14, Switzerland

    Wolf-Henning Boehncke

  3. Toronto Western Hospital, Toronto, Ontario, Canada

    Dafna D. Gladman

  4. Seattle Rheumatology Associates, Seattle, Washington, USA

    Philip J. Mease

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Soriano, E.R., Acosta Felquer, M.L. (2016). Oral Non-biologic Therapies and Non-pharmacological Therapies in PsA. In: Adebajo, A., Boehncke, WH., Gladman, D., Mease, P. (eds) Psoriatic Arthritis and Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-319-19530-8_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19530-8_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19529-2

  • Online ISBN: 978-3-319-19530-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation